ArticleFrontiers in endocrinology2025
Growth hormone therapy and chromosomal mosaicism in turner syndrome: 25 years of growth outcomes in Taiwan.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Turner syndrome (TS), a chromosomal disorder affecting females, is commonly associated with short stature due to haploinsufficiency of the SHOX gene. Recombinant human growth hormone (rhGH) and estrogen replacement therapy (ERT) are standard treatments to improve height and induce puberty. However, the impact of chromosomal mosaicism and other clinical variables on long-term growth outcomes remains controversial, particularly in Asian populations. Objective: To evaluate the influence of karyotype and other clinical predictors on growth velocity and final adult height in Taiwanese patients with TS undergoing rhGH and ERT. Methods: This 25-year retrospective multicenter study included 107 TS patients treated at three medical centers between 1997 and 2022. Patients were stratified into non-mosaic and mosaic karyotype groups. Growth patterns, treatment duration, and final adult height were assessed. Multivariable linear regression was used to identify predictors of growth outcome, including karyotype, bone age, baseline height, parental heights, IGF-1 levels, and pubertal status. Results: rhGH therapy began at a mean age of 11.0 ± 2.78 years (non-mosaic: 11.55 ± 2.76; mosaic: 10.50 ± 2.74). Patients with mosaic TS exhibited higher mean growth velocities during rhGH therapy without significant differences (p >0.05). ERT was initiated at a mean age of 15.10 ± 1.76 years in both groups. Heights at ERT initiation were 142.26 cm (non-mosaic) and 144.26 cm (mosaic). However, final adult height did not significantly differ between non-mosaic groups (148.31 ± 5.09 cm) and mosaic (149.39 ± 5.5 cm), respectively (p > 0.05). Regression analysis identified baseline bone age (β = -2.35, p < 0.0001), initial height (β = 0.55, p < 0.0001), and mid-parental height (β = 0.39, p = 0.0056) as significant predictors of final height. Karyotype, IGF-1, and pubertal status were not independently associated with growth outcomes. Conclusion: Growth hormone treatment in TS is beneficial, but final adult height is complex. Karyotype, including mosaicism, isn't a primary driver of adult height; instead, factors such as bone age at treatment initiation, pre-treatment height, and mid-parental height are stronger predictors. This emphasizes the need for early diagnosis, individualized treatment plans focusing on clinical assessments, and appropriately timed hormonal interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.